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Paracoccidioidomycosis (PCM) is an important systemic fungal disease, particularly among individuals
living and working in rural areas of endemicity in Latin America, who, without antifungal therapy, may develop
fatal acute or chronic infection. For such patients, the detection of antibody responses by immunodiffusion is
of limited value due to false-negative results. In contrast, the detection of Paracoccidioides brasiliensis gp43
circulating antigen may represent a more practical approach to the rapid diagnosis of the disease. Accordingly,
an inhibition enzyme-linked immunosorbent assay (inh-ELISA) was developed for the detection of a 43-kDa P.
brasiliensis-specific epitope incorporating a species-specific murine monoclonal antibody. With sera from
patients with acute and chronic forms of the disease (n  81), the overall sensitivity of the test was found to
be 95.1%, while specificity was found to be 97.5% compared to that with normal human sera from blood donors
(n  93) and sera from patients with other chronic fungal infections (histoplasmosis [n  33] and crypto-
coccosis [n 20]). The inh-ELISA detected circulating antigen in 100% of patients with the acute form of PCM
and in 95.31 and 100% of patients with the chronic multifocal and unifocal forms of PCM according to the
patient’s clinical presentation. Cerebrospinal fluid from 14 patients with neuroparacoccidioidomycosis and 13
samples of bronchoalveolar lavage fluid from patients with pulmonary unifocal PCM were also tested for gp43
detection, with the test showing 100% sensitivity and specificity. This novel, highly specific inh-ELISA repre-
sents a significant addition to the existing tests for the diagnosis of PCM.
Paracoccidioidomycosis (PCM) is a systemic granulomatous
disease caused by Paracoccidioides brasiliensis, a thermal di-
morphic fungus. PCM is widespread in Latin America, mainly
in Brazil, Argentina, Colombia, and Venezuela, affecting
mainly rural workers. According to McEwen et al. (22), ap-
proximately 10 million people may be infected with this fungus,
and up to 2% of them may develop the disseminated forms of
the disease. The incidence may increase due to forest destruc-
tion and a rise in iatrogenic immunosuppression procedures
(39). The acute or subacute form of PCM affects both sexes
and chiefly involves the reticuloendothelial system. The
chronic form affects adult males with predominantly pulmo-
nary and/or mucocutaneous involvement (12). A definitive di-
agnosis is usually made by visualization or isolation of the
fungus from the lesions, which is time-consuming and lacks
sensitivity. Detection of specific antibodies in serum has also
been one of the main tools for the diagnosis of PCM and may
be useful to monitor the evolution of the disease and its re-
sponse to treatment (24). The most common serological tests
used for diagnosis are immunodiffusion (4, 31), immunoenzy-
matic assays (3, 5, 25), and counterimmunoelectrophoresis (7).
Unfortunately, there is extensive antigenic cross-reactivity be-
tween P. brasiliensis and other fungi, limiting the value of the
tests that are currently employed. In view of cross-reactivity
and variations in the isolates used as sources for the production
of antigens, it is advisable to employ more than one test for
diagnosis of PCM
The gp43-glycoprotein from P. brasiliensis, secreted exocel-
lularly during the infective yeast phase (4, 28, 34), is the main
PCM diagnostic antigen (4, 28), being recognized by virtually
all sera from PCM patients in various test formats (1, 4, 25, 35,
36). With respect to cellular immunity, gp43 contains epitopes
which elicit positive delayed-type hypersensitivity in human
PCM patients (33). Taborda et al. (37) demonstrated that a
15-amino-acid peptide (P10) present in gp43 is responsible for
glycoprotein-mediated T-cell activation and protection against
PCM in BALB/c mice. As a receptor for laminin (38), gp43
may also be an important virulence factor.
A strong antibody response against gp43 is observed in PCM
patients and specific antibodies persist for a long time. De-
pending on their immune status, some diagnosed patients are
serologically negative at the time of diagnosis, with others
having low levels of specific antibodies for long periods of time.
Thus, it is doubtful whether these patients are ever cured (12).
In some invasive fungal diseases, the detection of circulating
antigen is a useful approach to the serodiagnosis (8, 11, 17, 21),
and this may also be an alternative tool for the diagnosis of
PCM patients. Some researchers have previously tried to de-
tect circulating antigen in PCM patients using polyvalent an-
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tigens or antibodies in different assays such as enzyme-linked
immunosorbent assay (ELISA) competition (14), immunora-
diometric assay (10), immunoelectrophoresis-immunodiffusion
(15), counterimmunoelectrophoresis (32), passive hemaggluti-
nation inhibition (20), inverted linear immunoelectrophoresis
(19), and immunoblotting (26). Gome´z et al. (16) were the first
investigators to use monoclonal antibodies for the detection of
an 87-kDa circulating antigen in PCM with 80.4% sensitivity.
Since gp43 represents the most important antigen of the P.
brasiliensis system and elicits antibodies that are useful both for
diagnosis and for monitoring patients undergoing treatment,
we report here the standardization of an alternative inhibition-
ELISA (inh-ELISA) for the detection of specific gp43 antigen
in serum, cerebrospinal fluid (CSF) and bronchoalveolar la-
vage (BAL) fluid using a monoclonal anti-gp43 antibody.
MATERIALS AND METHODS
Clinical samples. A total of 81 active PCM patients with a diagnosis estab-
lished by direct KOH examination, isolation by culture, and/or positive serolog-
ical tests were used in this study. One serum sample was taken from each patient
at the time of diagnosis. Samples were collected in Brazil between March 1990
and December 2001 at the Mycology Laboratory of Hospital Sa˜o Paulo, Sa˜o
Paulo; at the Department of Community Health, Federal University of Parana´
Medical School, Curitiba, Parana´; and at the Mycology Laboratory of UNI-
CAMP, Campinas, Sa˜o Paulo. Patients were classified according to their clinical
presentations. Of the 81 patients studied (73 males and 8 females), 11 had the
acute form of PCM and 70 had the chronic form (64 multifocal and 6 unifocal).
The mean age of patients with the acute form of the disease was 18.81 years,
whereas the mean age of patients with the chronic forms was 46.71. Serum
samples (n  53) obtained at the time of diagnosis from different patients with
other mycologically and/or serologically confirmed mycoses were also evaluated.
Ninety-three serum samples from healthy volunteers (blood donors) were in-
cluded as negative controls. To verify cross-reactions, 33 sera from individuals
with active histoplasmosis and 20 with cryptococcosis were also tested (Table 1).
In addition, we also tested 14 CSF samples and 13 BAL fluid samples obtained
from patients with neuroparacoccidioidomycosis and pulmonary PCM, respec-
tively. Also, 11 sample sera from these neuroparacoccidioidomycosis were tested.
Six CSF samples obtained from patients with no fungal diseases and 10 BAL fluid
samples from tuberculosis were used as negative controls (Table 2).
Fungal isolate, exoantigen preparation, and gp43 purification. P. brasiliensis
B-339 (ATCC 200273) was obtained from the culture collection of the Disciplina
de Biologia Celular da Universidade Federal de Sa˜o Paulo. The isolate was
transformed to the yeast phase, and exoantigen was produced according to
Camargo et al. (4). Gp43 was purified from this exoantigen as described else-
where (28). Protein determination was performed by the method of Bradford (2).
MAb production. Monoclonal antibody (MAb) was produced in our laboratory
by the method of Puccia and Travassos (29). Six-week-old BALB/c mice were
immunized every 3 weeks subcutaneously with 50 g of gp43 in phosphate-
buffered saline (PBS), incorporated into Freund’s complete adjuvant for the first
injection and in incomplete Freund’s adjuvant for the subsequent ones. Injec-
tions were always made at four different sites in the axillary and inguinal regions
in final volumes of 100 l per site. Before each immunization, mice were bled
through the ocular plexus, and the serum was separated by centrifugation and
stored at 20°C. Final immunization (50 g of gp43 in 100 l of PBS, intrave-
nously) was performed 2 days before cell fusion, according to the method of
Lopes and Alves (18). Screening of positive colonies was performed by an
enzyme immunoassay (EIA), as described later. After cloning by limiting dilution
and expanding positive clones, large amounts of antibodies were obtained by
producing ascites in BALB/c mice previously primed with Pristane (Sigma).
MAbs were purified from both culture supernatants and ascites fluids by affinity
chromatography on a protein A column. Immunoglobulin (Ig) isotyping was
performed with the Clone Selector mouse monoclonal antibody screening kit
(Bio-Rad) according to the manufacturer’s instructions.
Antibody screening by EIA. EIA was performed as described by Puccia and
Travassos (30). Briefly, polyvinyl microplates (Corning Costar) were coated with
50 l of a 2-g/ml solution of purified gp43 in PBS for 1 h at room temperature.
After blocking free sites with PBS containing 1% (vol/vol) bovine serum albumin
(Sigma) (PBS-BSA), 50 l of culture supernatant or purified MAbs was added to
each well. After 1 h of incubation at 37°C, wells were thoroughly washed with
PBS containing 0.5% gelatin (Difco) and 0.05% Tween 20 (Sigma) (PBS-T-G)
and treated with affinity-purified peroxidase-conjugated goat anti-mouse Ig (Bio-
Rad) for 1 h at 37°C, and this was followed by three washes with PBS-T-G.
Reactions were developed by the addition of o-phenylenediamine in 0.1 M
acetate-phosphate buffer, pH 5.8; stopped with 4 N sulfuric acid; and read in a
Titertek Multiskan EIA reader at 492 nm.
Pretreatment of immune sera for use in inh-ELISA. Aliquots of immune
serum (200 l) were mixed with an equal volume of 0.1 M EDTA (Sigma), pH
7.2, and boiled at 100°C for 3 to 5 min. The tubes were cooled and centrifuged
at 13,000g for 30 min. The supernatant was used for the test.
Inh-ELISA. The method described by Go´mez et al. (16) was followed. An
inh-ELISA test was developed for serum, CSF and BAL fluid samples. The
diluting buffer used in the serum experiments consisted of a pool of normal
human serum (NHS) 1:10 in 0.05% PBS–Tween 20 (PBS-Tween), 20 mM MgCl2,
and 1% bovine serum albumin (Sigma Chemical Co., St. Louis, Mo.). The
diluting buffer for experiments with CSF and BAL fluid was the same but
contained a pool of CSF or BAL fluid from individuals with no microbiological
disease, respectively, instead of NHS. Purified MAb 17C anti-gp43 was used at 10
g/ml, and all samples were tested 1:2 in diluting buffer.
Inibition plate. An inhibition standard curve was constructed by adding dif-
ferent concentrations of P. brasiliensis gp43 (from 1 ng to 30 g/ml) to 100 l of
pooled NHS (or CSF or BAL) and then adding 100 l of the standardized
concentration of MAb 17C. NHS, CSF, and BAL fluid made up 1:2 in diluting
buffer were used as negative controls. All standards, samples, and controls were
tested in triplicate. Samples were plated onto 96-well flat microtiter plates (Corn-
ing Costar) previously blocked by incubation with 200 l of 5% BSA per well
made up in PBS-Tween, for 2 h at 37°C. Plates were mixed in a shaker for 30 min
at room temperature and then incubated overnight at 4°C.
Reaction plate. Maxisorp polystyrene plates (Corning Costar) were coated
with 500 ng of gp43 in 0.06 M carbonate buffer, pH 9.6, per well (100 l/well).
TABLE 1. Detection of P. brasiliensis 43-kDa circulating antigen,
by inh-ELISA, in sera from various subjects
Serum group
No. of
serum
samples
tested
No. of
reactive
samplesa
No. of
nonreactive
samples
Reactive
samples
(%)
Mean
antigen
concn
(g/ml)
PCM
Acute 11 11 0 100 18.23
Chronic unifocal 6 6 0 100 7.64
Chronic multifocal 64 61 3 95.31 8.64
Histoplasmosis 33 0 33 0 0
Cryptococosis 20 0 20 0 0
NHS 93 3 90 3.22 0.08
a A sample was considered positive (i.e., reactive) if the antigen concentration
was 1.35 g/ml.
TABLE 2. Detection of P. brasiliensis gp43 antigen, by inh-ELISA,
in various specimens obtained from patients with PCM and
their respective controls
Specimen group
No. of
serum
samples
tested
No. of
reactive
samplesa
No. of
nonreactive
samples
Reactive
samples
(%)
Mean
antigen
concn
(g/ml)
BAL (from patients
with PCM)
13 13 0 100 16.06
CSF (from patients
with PCM)
14 14 0 100 19.26
Serum (from patients
with neuroparacoc-
cidioidomycosis)
11 10 1 90.9 4.59
BAL (control) 10 0 10 0 0
CSF (control) 6 0 6 0 0
NHS 30 0 30 0 0
a A sample was considered positive (i.e., reactive) if the antigen concentration
was 0.23 g/ml.
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The plates were left at room temperature for 30 min and then incubated over-
night at 4°C. After incubation, the plates were washed three times in PBS-Tween
and blocked by incubation with 200 l of 1% BSA in PBS per well for 1 h at 37°C;
after three more washes, 100 l from each well in the inhibition plate (containing
a mixture of the MAb-circulating complexes and free MAb) was transferred to
the respective wells in the reaction plate and allowed to stand for 2 h at 37°C.
After washing as described above, 100 l of goat anti-mouse IgG-peroxidase
(Sigma) was added and the plates were incubated for 1 h at 37°C. After further
washings, the reaction was developed with a solution of o-phenylenediamine (0.5
mg/ml; Sigma) and 0.005% H2O2. The reaction was stopped with 4 N H2SO4
after 8 to 10 min of incubation in the dark. Optical densities (ODs) were
measured at 490 nm with an ELISA reader (Titertek Multiskan EIA reader).
The OD at 492 nm was then plotted on a standard curve constructed from the
data derived from MAb titration with NHS containing known quantities of gp43
as described above. The degree of inhibition in MAb binding was shown to be
reciprocal to the concentration of circulating antigen in the sample.
The cutoff point was established as the receiver operator characteristic (ROC)
curve.
Statistical analysis. Data were analyzed statistically by the Stata 7.0 version for
Windows 98/95/NT (2001 release; Stata Corporation, College Station, Tex.) and
specificity, sensitivity and method efficiency were analyzed by the ROC curve.
Comparisons were made by one-way analysis of variance.
RESULTS
MAb production. A panel of different hybridoma lines reac-
tive to P. brasiliensis was produced. MAb 17C belongs to the
IgG1 subclass and recognizes an antigenic determinant of P.
brasiliensis by ELISA (data not shown) with a relative mass of
43 kDa by Western blotting. This MAb showed no reactivity
with Histoplasma capsulatum, Aspergillus fumigatus, or Candida
albicans exoantigens and was selected to develop an inh-
ELISA test.
Detection of P. brasiliensis antigenemia by inh-ELISA. Fig-
ure 1 illustrates the standard inhibition curve obtained with
known quantities of P. brasiliensis gp43. This curve was used to
determine the concentration of P. brasiliensis gp43 in each
sample tested. The sensitivity of the inh-ELISA ranged from
0.0053 to 30 g of antigen per ml of serum. The cut off point
was established by the ROC curve, based on the antigen con-
centration of PCM patients and NHS. Antigen concentrations
higher than 1.35 g/ml were considered to be a positive result.
Overall, 96.29% of the 81 PCM serum samples had detect-
able levels of circulating gp43 antigen above the cut off point
(Fig. 2), with a mean antigen concentration of 9.87 g/ml.
Table 1 and Fig. 3 show the results obtained when patients’
sera were separated according to the different clinical forms.
Circulating gp43 antigen was detectable in all patients with the
acute form of PCM (mean, 18.23 g/ml), and 95.71% of pa-
tients with the chronic form (mean, 8.55 g/ml). Among the
chronic form patients, those with the multifocal form (91.42%)
had a mean gp43 antigen concentration of 8.64 g/ml, and
those with the unifocal form (8.57%) had a mean gp43 level of
7.64 g/ml.
No cross-reactions were observed in heterologous serum
samples, specifically with sera from patients with histoplasmo-
sis or cryptococcosis. False-positive reactions were observed in
3.22% (3 of 93) of the NHS samples, although the mean an-
tigen concentration for this group was very low (0.08 g/ml).
Detection of P. brasiliensis gp43 in CSF by the inh-ELISA. A
standard inhibition curve was obtained and the cut off value
FIG. 1. Standard inhibition curve with MAb 17C constructed with
known quantities of purified gp43. Error bars, standard deviations.
FIG. 2. Detection of circulating antigen in sera from patients with
PCM or with other mycoses and in normal human sera by inh-ELISA.
Groups studied: 1, PCM (n  81); 2, cryptococcosis (n  20); 3,
histoplasmosis (n  33); 4, normal human sera (n  93). Bars repre-
sent the mean antigen concentration for each group. The long, fine line
represents the cutoff point (1.35 g/ml).
FIG. 3. Detection of circulating antigen in sera from patients with
different forms of PCM by Inh-ELISA. Groups studied: 1, acute form
(n  11); 2, chronic unifocal form (n  6); 3, chronic multifocal form
(n  64). Bars represent the mean antigen concentration for each
group. The long, fine line represents the cutoff point (1.35 g/ml).
VOL. 41, 2003 DETECTION OF CIRCULATING gp-43 ANTIGEN 3677
was determined as 0.23 g/ml, by the same method used for
sera. The sensitivity of the test with CSF was 100% and the
mean antigen concentration was equivalent to 19.26 g/ml.
CSF samples from individuals with diseases other than PCM
had undetectable antigen levels (Table 2 and Fig. 4).
Detection of P. brasiliensis gp43 in BAL fluid by the inh-
ELISA. A standard inhibition curve was obtained and the cut
off value was determined as 0.23 g/ml, by the same method
used for sera. The sensitivity of the test for BAL fluid samples
was 100% and the mean antigen concentration was equivalent
to 16.06 g/ml. BAL fluid samples from individuals with no
known infectious diseases had undetectable antigen levels (Ta-
ble 2 and Fig. 4).
Detection of P. brasiliensis gp43 in serum from neuropara-
coccidioidomycosis patients by the inh-ELISA. Serum samples
from patients with neuroparacoccidioidomycosis showed a
mean antigen concentration of 4.59 g/ml, less than that ob-
tained in CSF samples.
DISCUSSION
One of the main problems in the serodiagnosis of PCM
based on antibody detection is the cross-reaction obtained with
sera from patients with other mycoses, mainly histoplasmosis
and lobomycosis. Tests based on immunodiffusion are gener-
ally considered to have high specificity in the diagnosis of
PCM, but lack in sensitivity. In a previous paper we showed
that lack of reactivity of sera from PCM patients in immuno-
diffusion tests may be related to the production of low-avidity
IgG2 antibodies directed against carbohydrate epitopes (27).
Estimates of the sensitivity of immunodiffusion-based tests
vary from 65 to 100% (6) depending of the kind of antigen
preparation used. On the other hand, tests with higher sensi-
tivity, such as immunoenzymatic assays, present problems as-
sociated with specificity due to cross-reactivity with heterolo-
gous sera, i.e., patients with non-PCM fungal infections.
A more rational approach to the diagnosis of PCM may be
the detection of P. brasiliensis-gp43 antigen in body fluids. gp43
is a Pb yeast-phase extracellular antigen and its detection in
patients with proven PCM has been tested previously by many
approaches. However, these tests varied in sensitivity and spec-
ificity, and in most of the studies only a small number of
patients were analyzed.
Mendes-Giannini et al. (26) detected the gp43 antigen in
pools of PCM patients’ sera by Western blot assay, but no
quantitation was attempted. Freitas Da Silva and Roque-Bar-
reira (14), using competitive ELISA, detected circulating an-
tigens in 33.7% of 88 PCM patients’ sera, whose antigen levels
varied from 0.03 to 3.4 g/ml. However, cross-reactions were
obtained with heterologous sera, such as sera from patients
with aspergillosis, cryptococcosis and histoplasmosis.
The most refined study of PCM antigenemia was conducted
by Go´mez et al. (16) using monoclonal antibodies directed
against an 87-kDa antigen of Pb (gp87) in an inh-ELISA and
detected the presence of antigen in cases of PCM. In this study
antigen concentrations as low as 0.0058 g/ml of serum could
be detected in sera from 46 PCM patients with PCM, showing
80.4% sensitivity. Moreover, considering sera of patients with
the acute form of the disease, the inh-ELISA exhibited 100%
sensitivity, with the highest antigenemia (mean, 16.25 g/ml),
while 83.6% of the patients with the multifocal chronic form of
PCM showed a mean antigenemia of 14.92 g/ml and 60% of
patients with the chronic unifocal form showed a mean antigen
concentration of 14.7 g/ml. Cross-reactions with aspergillosis
and histoplasmosis were also observed. Also, the authors ob-
served cross-reactions with sera from patients with tuberculo-
sis. They assumed that coinfection with tuberculosis and PCM
was a possible explanation for these cross-reactions.
In our study, the inh-ELISA was able to detect gp43 antigen
in the concentration ranging from 0.0053 to 30 g/ml of serum.
The overall sensitivity of the test among 81 PCM patients was
95.1%, with a higher sensitivity in patients with the acute form
of PCM (100%) with a mean antigen concentration of 18.23
g/ml. Among the PCM patients with the chronic form, gp43
was detected in 95.71%, with mean concentration of 8.55 g/
ml. Our results showed that the gp43 detection assay can be
used for both clinical forms of the disease. Consequently, the
gp43 antigen detection test may be a valuable tool in PCM
diagnosis. Gp43 detection by this inh-ELISA showed 95.1%
sensitivity which was higher than the 80.4% sensitivity previ-
ously reported by Go´mez et al. to detect the 87-kDa antigen,
and also much higher than the 33.7% sensitivity previously
described by Freitas Da Silva and Roque-Barreira (14, 16).
The high percentage of positivity observed when the inh-
ELISA antigen test was used for the neuroparacoccidioidomy-
cosis group of patients, suggests that this test format may offer
a more sensitive test for this difficult to diagnose form of PCM.
Another interesting application for the inh-ELISA was the
detection of gp43 in BAL fluid specimens showing the high
sensitivity and specificity (100%) of the assay, since BAL fluid
is extremely diluted. This opens a new possibility in the diag-
nosis of PCM, when the disease is in its initial phase in the
FIG. 4. Detection of gp43 antigen in bronchoalveolar lavage from
patients with pulmonary PCM and in cerebrospinal fluid from patients
with neuroparacoccidioidomycosis by inh-ELISA. Groups studied: 1,
bronchoalveolar lavage fluid (n  13); 2, bronchoalveolar lavage fluid
of patients with no fungal pulmonary disease (n  10) (controls); 3,
cerebrospinal fluid from neuroparacoccidioidomycosis patients (n 
14); 4, cerebrospinal fluid from patients with no fungal disease (n 6);
5, serum from patients with neuroparacoccidioidomycosis (n  11).
Bars represent the average antigen concentration for each group. The
cutoff point was 0.23 g/ml.
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lungs and no sputum is available for direct observation of the
fungus.
Detection of low amounts of gp43 in some normal serum
controls may represents PCM subclinical infection in normal
people. PCM subclinical infection is defined as an asymptom-
atic infection caused by P. brasiliensis in normal individuals
who live in an endemic area and prove reactive to the para-
coccidioidin skin test (13). Positive paracoccidioidin skin test-
ing in health population may vary from 3.70 to 62.60%, de-
pending on the kind of antigenic preparation (9). In our
previous study, using gp43 or a polysaccharide antigen (Fava
Netto’s antigen) as paracoccidioidin, 5% of healthy people
reacted positively to both antigens (33).
Limited amounts of MAb anti-gp43 for detection of gp43
antigen can be provided by our laboratory to serve as standards
for those willing to prepare it in their own laboratories. Scaling
up of MAb production will depend on the number of requests
addressed to our department and on the costs involved.
In conclusion, we propose the use of inh-ELISA, using a
species-specific MAb, as an additional test for the diagnosis of
PCM in clinical laboratory. The use of the 43-kDa antigen
detection system described here will provide a rapid, sensitive,
and specific mean to diagnose and differentiate between acute
and chronic disease. Moreover, this test system’s true potential
may lie in tracking the course of antimycotic therapy by mon-
itoring the reduction in fungal load as evidenced by a sequen-
tial reduction in antigen detected. This will be the subject of
future studies.
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